Medical Oncologist
Before you start palbociclib
Who Is Eligible for — Palbociclib?
Palbociclib is not prescribed for every breast cancer. Two specific test results — hormone receptor status and HER2 status — determine whether it is the right treatment for you.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Two tests decide it — HR-positive and HER2-negative results on your biopsy report are the core requirement.
- Advanced disease only — Standard guidelines support palbociclib for metastatic or locally advanced inoperable breast cancer, not early-stage.
- Not a standalone drug — Palbociclib is always paired with hormone-blocking therapy — it is not given on its own.
- Prior CDK4/6 inhibitor rules you out — If you have already had palbociclib, ribociclib, or abemaciclib, you would not be given palbociclib again.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Palbociclib is prescribed for hormone receptor-positive (HR+), HER2-negative breast cancer that has spread or cannot be removed by surgery. NCCN and ESMO guidelines support this indication. Two test results must confirm your status — HR and HER2. You also need adequate organ function and no prior treatment with a CDK4/6 inhibitor.
What do the terms on your breast cancer report mean?
- HR-positive (HR+)
- Your tumour has receptors for oestrogen or progesterone, meaning hormones can drive its growth. This also means hormone-blocking drugs can slow it down — and palbociclib is designed to work alongside those drugs.
- HER2-negative
- Your tumour does not overexpress the HER2 protein. This is a required finding for palbociclib to be prescribed in the standard way.
- Advanced or metastatic breast cancer
- The cancer has spread to another part of the body — such as bone, liver, or lung — or has returned after earlier treatment in a way that cannot be removed surgically.
- CDK4/6 inhibitor
- A class of drugs that includes palbociclib, ribociclib, and abemaciclib. They slow the cell division cycle inside cancer cells. Having had any drug in this class before affects eligibility.
- Endocrine therapy
- Hormone-blocking treatment such as letrozole, anastrozole, or fulvestrant. Palbociclib is always combined with one of these drugs — it is not used alone.
Could you be eligible for palbociclib? Run through this list.
- Your breast cancer is confirmed HR-positive — ER-positive, PR-positive, or both — on your pathology report
- Your tumour is confirmed HER2-negative on testing
- Your cancer is advanced (Stage IV) or locally advanced and cannot be surgically removed
- You have not previously had palbociclib, ribociclib, abemaciclib, or any other CDK4/6 inhibitor
- Your blood counts and organ function are adequate — your oncologist will check this
- A plan for endocrine therapy alongside palbociclib has been discussed with you
Who is typically eligible and who is typically not?
| Feature | Typically eligible | Typically not eligible |
|---|---|---|
| Hormone receptor status | HR-positive (ER+ and/or PR+) | HR-negative |
| HER2 status | HER2-negative | HER2-positive |
| Disease stage | Advanced or metastatic (Stage IV), or locally advanced inoperable | Early stage — outside a clinical trial |
| Prior CDK4/6 inhibitor | None in this or any prior treatment line | Previously received one |
| Cancer type | Breast cancer | Other cancer types |
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What happens after your oncologist confirms you are eligible?
Your oncologist will pair palbociclib with an endocrine therapy drug. The choice depends on your menopausal status and what hormone-blocking treatment you have had before, if any.
If you have not had prior endocrine therapy, letrozole or anastrozole is commonly used alongside palbociclib as a first-line option, in line with NCCN and ESMO recommendations. If you have had prior endocrine therapy, fulvestrant is more commonly chosen.
Palbociclib is taken as a tablet for 21 days followed by a 7-day break. Blood counts are checked regularly because the drug can lower white blood cell levels.
What if you are not eligible for palbociclib?
Not being eligible does not mean being out of options. HR-positive, HER2-negative breast cancer has a range of effective treatments, and your oncologist will explain which fits your situation.
If your cancer is HER2-positive, drugs that target HER2 directly are the priority, and hormone-blocking treatment may still play a role alongside them. If your breast cancer is triple-negative, a different range of drugs applies.
Ask your oncologist which treatment is recommended and what it is intended to achieve for you.
Questions families ask most about palbociclib eligibility
What tests confirm I am eligible?
Two results from your biopsy tissue are needed. The first measures hormone receptor status — whether the tumour is ER-positive, PR-positive, or both. The second measures HER2 expression. Both are done on tissue from your biopsy, so a new biopsy is usually not required if one has already been done. Your oncologist reads the report and confirms whether the results support prescribing palbociclib.
Does my menopausal status affect whether I can have palbociclib?
Palbociclib is used in both premenopausal and postmenopausal women with HR-positive, HER2-negative advanced breast cancer. For premenopausal or perimenopausal women, an ovarian suppression injection is added alongside the endocrine therapy partner. Your menopausal status affects which partner drug is chosen and whether ovarian suppression is needed — it does not by itself determine whether you are eligible.
Can palbociclib be used for early-stage breast cancer?
Standard NCCN and ESMO guidelines currently recommend palbociclib for advanced or metastatic disease. It is not a standard treatment for early-stage breast cancer outside a clinical trial. If you have been diagnosed at an early stage and are asking about palbociclib, your oncologist can explain which drugs the evidence supports for your stage and whether any open trials are relevant to you.
I have had chemotherapy before. Does that affect my eligibility?
Prior chemotherapy does not rule you out. Eligibility is based on the biology of your tumour — HR-positive and HER2-negative — and on whether you have previously had a CDK4/6 inhibitor. Your chemotherapy history matters for understanding your full treatment picture, but it is not a barrier to palbociclib being considered.
What if my hormone receptor result is borderline or low?
Borderline results require careful interpretation, and your oncologist will discuss what the specific level means for your case. Very low hormone receptor expression can raise questions about how much the tumour is truly driven by hormones. If there is uncertainty about how to interpret your result, a second opinion from another pathologist or oncologist on the report is a reasonable step to consider.
Can palbociclib be stopped and restarted if side effects become difficult?
Yes, in many cases. Palbociclib can cause low white blood cell counts — a side effect called neutropenia — and the standard approach when this happens is a dose reduction or a short break rather than stopping permanently. Your oncologist monitors blood counts regularly for this reason. Decisions about pausing or reducing the dose are based on how severe the side effect is and how quickly counts recover.
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is palbociclib suitable for all types of breast cancer?
Palbociclib is only for HR-positive, HER2-negative breast cancer that is advanced or metastatic. It is not suitable for HER2-positive breast cancer, triple-negative breast cancer, or early-stage disease outside a clinical trial. Your oncologist will tell you which category your diagnosis falls into and which treatments the evidence supports.
How do I find out if my breast cancer is HR-positive and HER2-negative?
These results come from the pathology report on your biopsy tissue. The report states whether the tumour is ER-positive, PR-positive, or both — and what the HER2 result is. If you do not have a copy, ask your oncologist or the hospital's records office. A new biopsy is not needed if testing has already been done on earlier tissue.
Can men with breast cancer be considered for palbociclib?
Yes. Male breast cancer is most often HR-positive, and palbociclib may be considered if the other eligibility criteria are met. The evidence base in men is smaller because male breast cancer is less common, but NCCN guidance acknowledges its use. Your oncologist will assess based on your tumour characteristics and overall fitness.
Does palbociclib work if the cancer has spread to the brain?
Brain metastases add complexity that your oncologist will address specifically. Standard palbociclib trials have generally not included patients with active, untreated brain metastases, so the evidence in this setting is limited. If the cancer has spread to the brain, ask your oncologist directly what treatment options apply and what the goals of each would be.
How long does eligibility testing take before I can start?
If your biopsy report already includes HR and HER2 results, eligibility can often be confirmed at your next clinic appointment. If testing has not been done, results from tumour tissue usually take one to two weeks from when the sample reaches the laboratory. Your oncologist will tell you if any additional testing is needed before you can begin.
What should I bring to my appointment to discuss palbociclib?
Bring your pathology report if you have it, along with any recent scan reports. Write down the names and dates of previous treatments. Also list any other medicines you take, including supplements, vitamins, or ayurvedic preparations — some substances can interact with palbociclib. A complete picture helps your oncologist confirm eligibility accurately.